Bruce D. Jackson
Stock Analyst at Benchmark
(2.99)
# 1,537
Out of 5,102 analysts
9
Total ratings
87.5%
Success rate
34.38%
Average return
Main Sectors:
Stocks Rated by Bruce D. Jackson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EXAS Exact Sciences | Downgrades: Hold | n/a | $101.36 | - | 2 | Nov 24, 2025 | |
| MLSS Milestone Scientific | Maintains: Speculative Buy | $1.25 → $1 | $0.36 | +181.61% | 1 | Nov 20, 2025 | |
| HUMA Humacyte | Maintains: Buy | $14 → $11 | $1.31 | +739.69% | 1 | Nov 13, 2025 | |
| BLTE Belite Bio | Maintains: Buy | $80 → $132 | $150.24 | -12.14% | 1 | Oct 31, 2025 | |
| RVPH Reviva Pharmaceuticals Holdings | Maintains: Speculative Buy | $14 → $7 | $0.68 | +931.08% | 1 | Sep 15, 2025 | |
| UNCY Unicycive Therapeutics | Maintains: Speculative Buy | $3 → $21 | $6.41 | +227.61% | 1 | Sep 15, 2025 | |
| HBIO Harvard Bioscience | Maintains: Speculative Buy | $3 → $2 | $0.74 | +169.11% | 1 | Sep 10, 2025 | |
| CLNN Clene | Maintains: Buy | $33 → $31 | $6.88 | +350.58% | 1 | Sep 10, 2025 |
Exact Sciences
Nov 24, 2025
Downgrades: Hold
Price Target: n/a
Current: $101.36
Upside: -
Milestone Scientific
Nov 20, 2025
Maintains: Speculative Buy
Price Target: $1.25 → $1
Current: $0.36
Upside: +181.61%
Humacyte
Nov 13, 2025
Maintains: Buy
Price Target: $14 → $11
Current: $1.31
Upside: +739.69%
Belite Bio
Oct 31, 2025
Maintains: Buy
Price Target: $80 → $132
Current: $150.24
Upside: -12.14%
Reviva Pharmaceuticals Holdings
Sep 15, 2025
Maintains: Speculative Buy
Price Target: $14 → $7
Current: $0.68
Upside: +931.08%
Unicycive Therapeutics
Sep 15, 2025
Maintains: Speculative Buy
Price Target: $3 → $21
Current: $6.41
Upside: +227.61%
Harvard Bioscience
Sep 10, 2025
Maintains: Speculative Buy
Price Target: $3 → $2
Current: $0.74
Upside: +169.11%
Clene
Sep 10, 2025
Maintains: Buy
Price Target: $33 → $31
Current: $6.88
Upside: +350.58%